TY - JOUR AU - Jemal, A. AU - Siegel, R. AU - Ward, E. AU - Murray, T. AU - Xu, J. AU - Thun, M. J. PY - 2007 DA - 2007// TI - Cancer statistics, 2007 JO - CA Cancer J Clin VL - 57 UR - https://doi.org/10.3322/canjclin.57.1.43 DO - 10.3322/canjclin.57.1.43 ID - Jemal2007 ER - TY - JOUR AU - Pinthus, J. H. AU - Pacik, D. AU - Ramon, J. PY - 2007 DA - 2007// TI - Diagnosis of prostate cancer JO - Recent Results Cancer Res VL - 175 UR - https://doi.org/10.1007/978-3-540-40901-4_6 DO - 10.1007/978-3-540-40901-4_6 ID - Pinthus2007 ER - TY - JOUR AU - Pomerantz, M. AU - Kantoff, P. PY - 2007 DA - 2007// TI - Advances in the treatment of prostate cancer JO - Annu Rev Med VL - 58 UR - https://doi.org/10.1146/annurev.med.58.101505.115650 DO - 10.1146/annurev.med.58.101505.115650 ID - Pomerantz2007 ER - TY - JOUR AU - Chang, S. S. PY - 2006 DA - 2006// TI - Management of high risk metastatic prostate cancer: defining risk at the time of initial treatment failure JO - J Urol VL - 176 UR - https://doi.org/10.1016/j.juro.2006.06.068 DO - 10.1016/j.juro.2006.06.068 ID - Chang2006 ER - TY - JOUR AU - Loblaw, D. A. AU - Virgo, K. S. AU - Nam, R. AU - Somerfield, M. R. AU - Ben-Josef, E. AU - Mendelson, D. S. AU - Middleton, R. AU - Sharp, S. A. AU - Smith, T. J. AU - Talcott, J. PY - 2007 DA - 2007// TI - Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline JO - J Clin Oncol VL - 25 UR - https://doi.org/10.1200/JCO.2006.10.1949 DO - 10.1200/JCO.2006.10.1949 ID - Loblaw2007 ER - TY - JOUR AU - Mercader, M. AU - Sengupta, S. AU - Bodner, B. K. AU - Manecke, R. G. AU - Cosar, E. F. AU - Moser, M. T. AU - Ballman, K. V. AU - Wojcik, E. M. AU - Kwon, E. D. PY - 2007 DA - 2007// TI - Early effects of pharmacological androgen deprivation in human prostate cancer JO - BJU Int VL - 99 UR - https://doi.org/10.1111/j.1464-410X.2007.06538.x DO - 10.1111/j.1464-410X.2007.06538.x ID - Mercader2007 ER - TY - JOUR AU - Wagner, M. AU - Garzotto, M. AU - Lemmon, D. AU - Eilers, K. M. AU - Beer, T. M. PY - 2005 DA - 2005// TI - Prostate-specific antigen decline after gonadotropin-releasing hormone antagonist withdrawal in androgen-independent prostate cancer JO - Urology VL - 65 UR - https://doi.org/10.1016/j.urology.2004.10.059 DO - 10.1016/j.urology.2004.10.059 ID - Wagner2005 ER - TY - JOUR AU - Tannock, I. F. AU - de Wit, R. AU - Berry, W. R. AU - Horti, J. AU - Pluzanska, A. AU - Chi, K. N. AU - Oudard, S. AU - Theodore, C. AU - James, N. D. AU - Turesson, I. PY - 2004 DA - 2004// TI - Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer JO - N Engl J Med VL - 351 UR - https://doi.org/10.1056/NEJMoa040720 DO - 10.1056/NEJMoa040720 ID - Tannock2004 ER - TY - JOUR AU - Sowery, R. D. AU - So, A. I. AU - Gleave, M. E. PY - 2007 DA - 2007// TI - Therapeutic options in advanced prostate cancer: present and future JO - Curr Urol Rep VL - 8 UR - https://doi.org/10.1007/s11934-007-0021-9 DO - 10.1007/s11934-007-0021-9 ID - Sowery2007 ER - TY - JOUR AU - Shawver, L. K. AU - Slamon, D. AU - Ullrich, A. PY - 2002 DA - 2002// TI - Smart drugs: tyrosine kinase inhibitors in cancer therapy JO - Cancer Cell VL - 1 UR - https://doi.org/10.1016/S1535-6108(02)00039-9 DO - 10.1016/S1535-6108(02)00039-9 ID - Shawver2002 ER - TY - JOUR AU - Krause, D. S. AU - Van Etten, R. A. PY - 2005 DA - 2005// TI - Tyrosine kinases as targets for cancer therapy JO - N Engl J Med VL - 353 UR - https://doi.org/10.1056/NEJMra044389 DO - 10.1056/NEJMra044389 ID - Krause2005 ER - TY - JOUR AU - Hochhaus, A. PY - 2004 DA - 2004// TI - Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST) JO - Ann Hematol VL - 83 ID - Hochhaus2004 ER - TY - JOUR AU - de Jager, J. AU - Stebbing, J. PY - 2006 DA - 2006// TI - Erlotinib or capecitabine with gemcitabine in pancreatic cancer? JO - Future Oncol VL - 2 UR - https://doi.org/10.2217/14796694.2.2.161 DO - 10.2217/14796694.2.2.161 ID - de Jager2006 ER - TY - JOUR AU - Pawson, T. PY - 2004 DA - 2004// TI - Specificity in signal transduction: from phosphotyrosine-SH2 domain interactions to complex cellular systems JO - Cell VL - 116 UR - https://doi.org/10.1016/S0092-8674(03)01077-8 DO - 10.1016/S0092-8674(03)01077-8 ID - Pawson2004 ER - TY - JOUR AU - Schlessinger, J. PY - 2000 DA - 2000// TI - Cell signaling by receptor tyrosine kinases JO - Cell VL - 103 UR - https://doi.org/10.1016/S0092-8674(00)00114-8 DO - 10.1016/S0092-8674(00)00114-8 ID - Schlessinger2000 ER - TY - JOUR AU - Hofer, M. D. AU - Fecko, A. AU - Shen, R. AU - Setlur, S. R. AU - Pienta, K. G. AU - Tomlins, S. A. AU - Chinnaiyan, A. M. AU - Rubin, M. A. PY - 2004 DA - 2004// TI - Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors JO - Neoplasia VL - 6 UR - https://doi.org/10.1593/neo.04157 DO - 10.1593/neo.04157 ID - Hofer2004 ER - TY - JOUR AU - Robinson, D. AU - He, F. AU - Pretlow, T. AU - Kung, H. J. PY - 1996 DA - 1996// TI - A tyrosine kinase profile of prostate carcinoma JO - Proc Natl Acad Sci USA VL - 93 UR - https://doi.org/10.1073/pnas.93.12.5958 DO - 10.1073/pnas.93.12.5958 ID - Robinson1996 ER - TY - JOUR AU - Singh, D. AU - Febbo, P. G. AU - Ross, K. AU - Jackson, D. G. AU - Manola, J. AU - Ladd, C. AU - Tamayo, P. AU - Renshaw, A. A. AU - D'Amico, A. V. AU - Richie, J. P. PY - 2002 DA - 2002// TI - Gene expression correlates of clinical prostate cancer behavior JO - Cancer Cell VL - 1 UR - https://doi.org/10.1016/S1535-6108(02)00030-2 DO - 10.1016/S1535-6108(02)00030-2 ID - Singh2002 ER - TY - JOUR AU - El Sheikh, S. S. AU - Domin, J. AU - Abel, P. AU - Stamp, G. AU - Lalani el, N. PY - 2004 DA - 2004// TI - Phosphorylation of both EGFR and ErbB2 is a reliable predictor of prostate cancer cell proliferation in response to EGF JO - Neoplasia VL - 6 UR - https://doi.org/10.1593/neo.04379 DO - 10.1593/neo.04379 ID - El Sheikh2004 ER - TY - JOUR AU - Majumder, P. K. AU - Sellers, W. R. PY - 2005 DA - 2005// TI - Akt-regulated pathways in prostate cancer JO - Oncogene VL - 24 UR - https://doi.org/10.1038/sj.onc.1209096 DO - 10.1038/sj.onc.1209096 ID - Majumder2005 ER - TY - JOUR AU - Ghosh, P. M. AU - Malik, S. N. AU - Bedolla, R. G. AU - Wang, Y. AU - Mikhailova, M. AU - Prihoda, T. J. AU - Troyer, D. A. AU - Kreisberg, J. I. PY - 2005 DA - 2005// TI - Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation JO - Endocr Relat Cancer VL - 12 UR - https://doi.org/10.1677/erc.1.00835 DO - 10.1677/erc.1.00835 ID - Ghosh2005 ER - TY - JOUR AU - Lin, J. AU - Adam, R. M. AU - Santiestevan, E. AU - Freeman, M. R. PY - 1999 DA - 1999// TI - The phosphatidylinositol 3'-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells JO - Cancer Res VL - 59 ID - Lin1999 ER - TY - JOUR AU - Liao, Y. AU - Grobholz, R. AU - Abel, U. AU - Trojan, L. AU - Michel, M. S. AU - Angel, P. AU - Mayer, D. PY - 2003 DA - 2003// TI - Increase of AKT/PKB expression correlates with gleason pattern in human prostate cancer JO - Int J Cancer VL - 107 UR - https://doi.org/10.1002/ijc.11471 DO - 10.1002/ijc.11471 ID - Liao2003 ER - TY - JOUR AU - Graff, J. R. AU - Konicek, B. W. AU - McNulty, A. M. AU - Wang, Z. AU - Houck, K. AU - Allen, S. AU - Paul, J. D. AU - Hbaiu, A. AU - Goode, R. G. AU - Sandusky, G. E. PY - 2000 DA - 2000// TI - Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression JO - J Biol Chem VL - 275 UR - https://doi.org/10.1074/jbc.M003145200 DO - 10.1074/jbc.M003145200 ID - Graff2000 ER - TY - JOUR AU - Kreisberg, J. I. AU - Malik, S. N. AU - Prihoda, T. J. AU - Bedolla, R. G. AU - Troyer, D. A. AU - Kreisberg, S. AU - Ghosh, P. M. PY - 2004 DA - 2004// TI - Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer JO - Cancer Res VL - 64 UR - https://doi.org/10.1158/0008-5472.CAN-04-0272 DO - 10.1158/0008-5472.CAN-04-0272 ID - Kreisberg2004 ER - TY - JOUR AU - Le Page, C. AU - Koumakpayi, I. H. AU - Alam-Fahmy, M. AU - Mes-Masson, A. M. AU - Saad, F. PY - 2006 DA - 2006// TI - Expression and localisation of Akt-1, Akt-2 and Akt-3 correlate with clinical outcome of prostate cancer patients JO - Br J Cancer VL - 94 UR - https://doi.org/10.1038/sj.bjc.6603184 DO - 10.1038/sj.bjc.6603184 ID - Le Page2006 ER - TY - JOUR AU - Litman, P. AU - Ohne, O. AU - Ben-Yaakov, S. AU - Shemesh-Darvish, L. AU - Yechezkel, T. AU - Salitra, Y. AU - Rubnov, S. AU - Cohen, I. AU - Senderowitz, H. AU - Kidron, D. PY - 2007 DA - 2007// TI - A novel substrate mimetic inhibitor of PKB/Akt inhibits prostate cancer tumor growth in mice by blocking the PKB pathway JO - Biochemistry VL - 46 UR - https://doi.org/10.1021/bi061928s DO - 10.1021/bi061928s ID - Litman2007 ER - TY - JOUR AU - Li, B. AU - Sun, A. AU - Youn, H. AU - Hong, Y. AU - Terranova, P. F. AU - Thrasher, J. B. AU - Xu, P. AU - Spencer, D. PY - 2007 DA - 2007// TI - Conditional Akt activation promotes androgen-independent progression of prostate cancer JO - Carcinogenesis VL - 28 UR - https://doi.org/10.1093/carcin/bgl193 DO - 10.1093/carcin/bgl193 ID - Li2007 ER - TY - JOUR AU - Pienta, K. J. AU - Bradley, D. PY - 2006 DA - 2006// TI - Mechanisms underlying the development of androgen-independent prostate cancer JO - Clin Cancer Res VL - 12 UR - https://doi.org/10.1158/1078-0432.CCR-06-0067 DO - 10.1158/1078-0432.CCR-06-0067 ID - Pienta2006 ER - TY - JOUR AU - Murillo, H. AU - Huang, H. AU - Schmidt, L. J. AU - Smith, D. I. AU - Tindall, D. J. PY - 2001 DA - 2001// TI - Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state JO - Endocrinology VL - 142 UR - https://doi.org/10.1210/endo.142.11.8467 DO - 10.1210/endo.142.11.8467 ID - Murillo2001 ER - TY - JOUR AU - Lu, S. AU - Ren, C. AU - Liu, Y. AU - Epner, D. E. PY - 2006 DA - 2006// TI - PI3K-Akt signaling is involved in the regulation of p21(WAF/CIP) expression and androgen-independent growth in prostate cancer cells JO - Int J Oncol VL - 28 ID - Lu2006 ER - TY - JOUR AU - Pfeil, K. AU - Eder, I. E. AU - Putz, T. AU - Ramoner, R. AU - Culig, Z. AU - Ueberall, F. AU - Bartsch, G. AU - Klocker, H. PY - 2004 DA - 2004// TI - Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells JO - Prostate VL - 58 UR - https://doi.org/10.1002/pros.10332 DO - 10.1002/pros.10332 ID - Pfeil2004 ER - TY - JOUR AU - Qi, W. AU - Martinez, J. D. PY - 2003 DA - 2003// TI - Reduction of 14-3-3 proteins correlates with increased sensitivity to killing of human lung cancer cells by ionizing radiation JO - Radiat Res VL - 160 UR - https://doi.org/10.1667/RR3038 DO - 10.1667/RR3038 ID - Qi2003 ER - TY - JOUR AU - Horoszewicz, J. S. AU - Leong, S. S. AU - Kawinski, E. AU - Karr, J. P. AU - Rosenthal, H. AU - Chu, T. M. AU - Mirand, E. A. AU - Murphy, G. P. PY - 1983 DA - 1983// TI - LNCaP model of human prostatic carcinoma JO - Cancer Res VL - 43 ID - Horoszewicz1983 ER - TY - JOUR AU - Kubler, H. R. AU - van Randenborgh, H. AU - Treiber, U. AU - Wutzler, S. AU - Battistel, C. AU - Lehmer, A. AU - Wagenpfeil, S. AU - Hartung, R. AU - Paul, R. PY - 2005 DA - 2005// TI - In vitro cytotoxic effects of imatinib in combination with anticancer drugs in human prostate cancer cell lines JO - Prostate VL - 63 UR - https://doi.org/10.1002/pros.20201 DO - 10.1002/pros.20201 ID - Kubler2005 ER - TY - JOUR AU - Secrist, J. P. AU - Burns, L. A. AU - Karnitz, L. AU - Koretzky, G. A. AU - Abraham, R. T. PY - 1993 DA - 1993// TI - Stimulatory effects of the protein tyrosine phosphatase inhibitor, pervanadate, on T-cell activation events JO - J Biol Chem VL - 268 ID - Secrist1993 ER - TY - JOUR AU - Hsieh, A. C. AU - Moasser, M. M. PY - 2007 DA - 2007// TI - Targeting HER proteins in cancer therapy and the role of the non-target HER3 JO - Br J Cancer VL - 97 UR - https://doi.org/10.1038/sj.bjc.6603910 DO - 10.1038/sj.bjc.6603910 ID - Hsieh2007 ER - TY - JOUR AU - Aziz, M. H. AU - Nihal, M. AU - Fu, V. X. AU - Jarrard, D. F. AU - Ahmad, N. PY - 2006 DA - 2006// TI - Resveratrol-caused apoptosis of human prostate carcinoma LNCaP cells is mediated via modulation of phosphatidylinositol 3'-kinase/Akt pathway and Bcl-2 family proteins JO - Mol Cancer Ther VL - 5 UR - https://doi.org/10.1158/1535-7163.MCT-05-0526 DO - 10.1158/1535-7163.MCT-05-0526 ID - Aziz2006 ER - TY - JOUR AU - Yang, Y. AU - Ikezoe, T. AU - Takeuchi, T. AU - Adachi, Y. AU - Ohtsuki, Y. AU - Koeffler, H. P. AU - Taguchi, H. PY - 2006 DA - 2006// TI - Zanthoxyli Fructus induces growth arrest and apoptosis of LNCaP human prostate cancer cells in vitro and in vivo in association with blockade of the AKT and AR signal pathways JO - Oncol Rep VL - 15 ID - Yang2006 ER - TY - JOUR AU - Nelson, E. C. AU - Evans, C. P. AU - Mack, P. C. AU - Devere-White, R. W. AU - Lara, P. N. PY - 2007 DA - 2007// TI - Inhibition of Akt pathways in the treatment of prostate cancer JO - Prostate Cancer Prostatic Dis VL - 10 UR - https://doi.org/10.1038/sj.pcan.4500974 DO - 10.1038/sj.pcan.4500974 ID - Nelson2007 ER - TY - JOUR AU - Gioeli, D. PY - 2005 DA - 2005// TI - Signal transduction in prostate cancer progression JO - Clin Sci (Lond) VL - 108 UR - https://doi.org/10.1042/CS20040329 DO - 10.1042/CS20040329 ID - Gioeli2005 ER - TY - JOUR AU - Grasso, A. W. AU - Wen, D. AU - Miller, C. M. AU - Rhim, J. S. AU - Pretlow, T. G. AU - Kung, H. J. PY - 1997 DA - 1997// TI - ErbB kinases and NDF signaling in human prostate cancer cells JO - Oncogene VL - 15 UR - https://doi.org/10.1038/sj.onc.1201447 DO - 10.1038/sj.onc.1201447 ID - Grasso1997 ER - TY - JOUR AU - Koumakpayi, I. H. AU - Diallo, J. S. AU - Le Page, C. AU - Lessard, L. AU - Gleave, M. AU - Begin, L. R. AU - Mes-Masson, A. M. AU - Saad, F. PY - 2006 DA - 2006// TI - Expression and nuclear localization of ErbB3 in prostate cancer JO - Clin Cancer Res VL - 12 UR - https://doi.org/10.1158/1078-0432.CCR-05-2242 DO - 10.1158/1078-0432.CCR-05-2242 ID - Koumakpayi2006 ER - TY - JOUR AU - Munster, P. N. AU - Marchion, D. C. AU - Basso, A. D. AU - Rosen, N. PY - 2002 DA - 2002// TI - Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway JO - Cancer Res VL - 62 ID - Munster2002 ER - TY - JOUR AU - Kominsky, S. L. AU - Hobeika, A. C. AU - Lake, F. A. AU - Torres, B. A. AU - Johnson, H. M. PY - 2000 DA - 2000// TI - Down-regulation of neu/HER-2 by interferon-gamma in prostate cancer cells JO - Cancer Res VL - 60 ID - Kominsky2000 ER - TY - JOUR AU - Nasu, K. AU - Tanji, N. AU - Nishioka, R. AU - Wang, J. AU - Yanagihara, Y. AU - Ozawa, A. AU - Yokoyama, M. AU - Sakayama, K. PY - 2006 DA - 2006// TI - EXpression of ErbB proteins in human prostate JO - Arch Androl VL - 52 UR - https://doi.org/10.1080/01485010500316238 DO - 10.1080/01485010500316238 ID - Nasu2006 ER - TY - JOUR AU - Ratan, H. L. AU - Gescher, A. AU - Steward, W. P. AU - Mellon, J. K. PY - 2003 DA - 2003// TI - ErbB receptors: possible therapeutic targets in prostate cancer? JO - BJU Int VL - 92 UR - https://doi.org/10.1111/j.1464-410X.2003.04503.x DO - 10.1111/j.1464-410X.2003.04503.x ID - Ratan2003 ER - TY - JOUR AU - Normanno, N. AU - Campiglio, M. AU - De, L. A. AU - Somenzi, G. AU - Maiello, M. AU - Ciardiello, F. AU - Gianni, L. AU - Salomon, D. S. AU - Menard, S. PY - 2002 DA - 2002// TI - Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth JO - Ann Oncol VL - 13 UR - https://doi.org/10.1093/annonc/mdf020 DO - 10.1093/annonc/mdf020 ID - Normanno2002 ER - TY - JOUR AU - Arteaga, C. L. PY - 2007 DA - 2007// TI - HER3 and mutant EGFR meet MET JO - Nat Med VL - 13 UR - https://doi.org/10.1038/nm0607-675 DO - 10.1038/nm0607-675 ID - Arteaga2007 ER - TY - JOUR AU - Engelman, J. A. AU - Zejnullahu, K. AU - Mitsudomi, T. AU - Song, Y. AU - Hyland, C. AU - Park, J. O. AU - Lindeman, N. AU - Gale, C. M. AU - Zhao, X. AU - Christensen, J. PY - 2007 DA - 2007// TI - MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling JO - Science VL - 316 UR - https://doi.org/10.1126/science.1141478 DO - 10.1126/science.1141478 ID - Engelman2007 ER - TY - JOUR AU - Mahadevan, D. AU - Cooke, L. AU - Riley, C. AU - Swart, R. AU - Simons, B. AU - Della Croce, K. AU - Wisner, L. AU - Iorio, M. AU - Shakalya, K. AU - Garewal, H. PY - 2007 DA - 2007// TI - A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors JO - Oncogene VL - 26 UR - https://doi.org/10.1038/sj.onc.1210173 DO - 10.1038/sj.onc.1210173 ID - Mahadevan2007 ER - TY - STD TI - The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/9/142/prepub UR - http://www.biomedcentral.com/1471-2407/9/142/prepub ID - ref52 ER -